Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $12.1 million.

  • Syndax Pharmaceuticals' Share-based Compensation rose 124.02% to $12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.5 million, marking a year-over-year increase of 2429.84%. This contributed to the annual value of $43.0 million for FY2024, which is 3901.33% up from last year.
  • Syndax Pharmaceuticals' Share-based Compensation amounted to $12.1 million in Q3 2025, which was up 124.02% from $13.8 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Share-based Compensation high stood at $13.8 million for Q2 2025, and its period low was $2.8 million during Q1 2021.
  • Its 5-year average for Share-based Compensation is $7.3 million, with a median of $8.1 million in 2023.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Share-based Compensation soared by 10479.94% in 2023 and then soared by 124.02% in 2025.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Share-based Compensation stood at $3.9 million in 2021, then rose by 7.94% to $4.2 million in 2022, then soared by 96.35% to $8.3 million in 2023, then skyrocketed by 47.68% to $12.3 million in 2024, then decreased by 1.75% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q3 2025, $13.8 million for Q2 2025, and $10.4 million during Q1 2025.